Stryker Corporation Q2 2025 Earnings Recap

Stryker delivered robust second quarter results, achieving a 10.2% organic sales growth and an 11.4% increase in adjusted EPS, driven by strong performance across its MedSurg, Neurotechnology, and orthopedic segments.

Key Takeaways

• U.S. organic sales growth was particularly strong at 11.5%, with notable contributions from Endoscopy and neurocranial businesses.
• International sales grew 6.5% despite supply chain challenges, with emerging markets showing promising demand.
• Stryker is on track to boost its full-year 2025 outlook and anticipates an additional 100 basis points of operating margin expansion.
• The integration of recent acquisitions is progressing, with expectations of double-digit pro forma growth for 2025.
• An impressive milestone of 2 million robotic procedures performed with Mako reinforces Stryker’s leadership in orthopedic robotics.